Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel ...
Stocktwits on MSN
Theriva™ Biologics reports full-year 2025 operational highlights and financial results
Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma – – Licensed SYN-020 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results